Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6794578 | 0.89 | SMN1; SMN2 (0.45) | ROCK2SMN1; SMN2ALDH1A1HPGDHTT | |
| SCHEMBL6795268 | 0.89 | NPC1 (0.38) | SMN1; SMN2 | |
| SCHEMBL6800589 | 0.87 | NAMPT (0.42) | ROCK2SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL6791640 | 0.86 | ALDH1A1 (0.43) | SMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL6794149 | 0.84 | HTR5A (0.38) | ROCK2ALDH1A1 | |
| SCHEMBL1655698 | 0.83 | CYP1A2 (0.30) | HPGD | |
| SCHEMBL6791548 | 0.83 | CYP1A2 (0.33) | ALDH1A1HPGDHTT | |
| SCHEMBL6794266 | 0.83 | KMT2A (0.41) | ROCK2SMN1; SMN2ALDH1A1HTT | |
| SCHEMBL6800306 | 0.82 | NAMPT (0.38) | SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL6792951 | 0.81 | CYP1A2 (0.37) | HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | ROCK2 317/4885SMN1; SMN2 4333/4885ALDH1A1 4449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.